 | • レポートコード：MRC2304A101 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、259ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥692,860 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,392,860 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に4,241.55百万ドルであった世界の創傷用生物製剤市場規模が2022年に4,585.62百万ドルに到達し、2027年までにCAGR 9.15％で成長して7,175.51百万ドルへと拡大すると予測しています。当調査資料では、創傷用生物製剤の世界市場について多角的な視点から分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別（生物学的代用皮膚、局所薬）分析、創傷タイプ別（熱傷、外科的＆外傷性創傷、潰瘍）分析、エンドユーザー別（外来手術センター、熱傷センター、病院、創傷クリニック）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめました。なお、当書内の企業情報としては、3M Company、Anika Therapeutics, Inc、Avita Medical, Inc.、Bioventus Inc.、ConvaTec Group PLC、Cytori Therapeutics Inc.、Integra Lifesciences Holdings Corporation、Kerecis hf、Marine Polymer Technologies, Inc.、MIMEDX GROUP, INC.、Mölnlycke Health Care ABなどが掲載されています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の創傷用生物製剤市場規模：製品別 - 生物学的代用皮膚の市場規模 - 局所薬の市場規模 ・世界の創傷用生物製剤市場規模：創傷タイプ別 - 熱傷における市場規模 - 外科的＆外傷性創傷における市場規模 - 潰瘍における市場規模 ・世界の創傷用生物製剤市場規模：エンドユーザー別 - 外来手術センターにおける市場規模 - 熱傷センターにおける市場規模 - 病院における市場規模 - 創傷クリニックにおける市場規模 ・世界の創傷用生物製剤市場規模：地域別 - 南北アメリカの創傷用生物製剤市場規模 アメリカの創傷用生物製剤市場規模 カナダの創傷用生物製剤市場規模 ブラジルの創傷用生物製剤市場規模 ... - アジア太平洋の創傷用生物製剤市場規模 日本の創傷用生物製剤市場規模 中国の創傷用生物製剤市場規模 インドの創傷用生物製剤市場規模 韓国の創傷用生物製剤市場規模 台湾の創傷用生物製剤市場規模 ... - ヨーロッパ/中東/アフリカの創傷用生物製剤市場規模 イギリスの創傷用生物製剤市場規模 ドイツの創傷用生物製剤市場規模 フランスの創傷用生物製剤市場規模 ロシアの創傷用生物製剤市場規模 ... - その他地域の創傷用生物製剤市場規模 ・競争状況 ・企業情報 |
The Global Wound Biologics Market size was estimated at USD 4,241.55 million in 2021 and expected to reach USD 4,585.62 million in 2022, and is projected to grow at a CAGR 9.15% to reach USD 7,175.51 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Wound Biologics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Biologic Skin Substitutes and Topical Agents. The Biologic Skin Substitutes is further studied across Acellular Animal-derived Products, Biosynthetic Products, and Human Donor Tissue-derived Products.
Based on Wound Type, the market was studied across Burns, Surgical and Traumatic Wounds, and Ulcers. The Ulcers is further studied across Diabetic Foot Ulcers, Pressure Ulcers, and Venous Ulcers.
Based on End-User, the market was studied across Ambulatory Surgery Centers, Burn Centers, Hospitals, and Wound Clinics.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Connecticut, Florida, Illinois, Maryland, Minnesota, New Jersey, New York, Ohio, Pennsylvania, Texas, and Washington. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Wound Biologics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Wound Biologics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Wound Biologics Market, including 3M Company, Anika Therapeutics, Inc, Avita Medical, Inc., Bioventus Inc., ConvaTec Group PLC, Cytori Therapeutics Inc., Integra Lifesciences Holdings Corporation, Kerecis hf, Marine Polymer Technologies, Inc., MIMEDX GROUP, INC., Mölnlycke Health Care AB, Nuo Therapeutics, Inc., Organogenesis Inc., Skye Biologics Holdings, LLC, Smith & Nephew PLC, Stability Biologics, Stryker Corporation, Tides Medical, Vericel Corporation, and Viatris Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Wound Biologics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Wound Biologics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Wound Biologics Market?
4. What is the competitive strategic window for opportunities in the Global Wound Biologics Market?
5. What are the technology trends and regulatory frameworks in the Global Wound Biologics Market?
6. What is the market share of the leading vendors in the Global Wound Biologics Market?
7. What modes and strategic moves are considered suitable for entering the Global Wound Biologics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Government Initiatives Regarding Wound Care Treatment
5.1.1.2. Rising Incidences of Burn Injuries and Road Accidents
5.1.1.3. Increasing Geriatric Population Globally
5.1.2. Restraints
5.1.2.1. High Cost of Wound Treatment
5.1.3. Opportunities
5.1.3.1. Introduction of Innovative Wound Care Biologics
5.1.3.2. Potential Need for Bioengineered Skin Substitutes in Surgeries
5.1.4. Challenges
5.1.4.1. Lack of Trained Physicians and Complications Associated with the Contamination
5.2. Cumulative Impact of COVID-19
6. Wound Biologics Market, by Product
6.1. Introduction
6.2. Biologic Skin Substitutes
6.3.1. Acellular Animal-derived Products
6.3.2. Biosynthetic Products
6.3.3. Human Donor Tissue-derived Products
6.3. Topical Agents
7. Wound Biologics Market, by Wound Type
7.1. Introduction
7.2. Burns
7.3. Surgical and Traumatic Wounds
7.4. Ulcers
7.5.1. Diabetic Foot Ulcers
7.5.2. Pressure Ulcers
7.5.3. Venous Ulcers
8. Wound Biologics Market, by End-User
8.1. Introduction
8.2. Ambulatory Surgery Centers
8.3. Burn Centers
8.4. Hospitals
8.5. Wound Clinics
9. Americas Wound Biologics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Wound Biologics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Wound Biologics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. 3M Company
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Anika Therapeutics, Inc
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Avita Medical, Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Bioventus Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. ConvaTec Group PLC
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Cytori Therapeutics Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Integra Lifesciences Holdings Corporation
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Kerecis hf
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Marine Polymer Technologies, Inc.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. MIMEDX GROUP, INC.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Mölnlycke Health Care AB
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Nuo Therapeutics, Inc.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Organogenesis Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Skye Biologics Holdings, LLC
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Smith & Nephew PLC
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Stability Biologics
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Stryker Corporation
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Tides Medical
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Vericel Corporation
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Viatris Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing